U.S. Markets open in 4 hrs 26 mins

Cortexyme's unique approach to Alzheimer's research

Biopharmaceutical company Cortexyme is currently in a clinical trial stage, researching what they believe is a new way to treat the cause of Alzheimer's disease and other degenerative diseases. Cortexyme Co-Founder, Chairperson and CEO Casey Lynch sits down with Yahoo Finance's Adam Shapiro, Julie Hyman, and Scott Gamm to discuss.